Abstract
In this work, we report a complete response case of a 69-year-old male with metastatic prostate cancer (initial prostate-specific antigen (PSA)=26.3 ng/mL, Gleason score 3+4=7, cT3a, N0, M1b) treated with triplet therapy comprising leuprorelin + docetaxel (75 mg/m(2)/3 weeks) + darolutamide (1,200 mg/d). His PSA was checked monthly, and radiological scans (computed tomography and bone scans) were administered every three months. His PSA declined quickly, reaching <0.01 ng/mL five months after starting triplet therapy, but his bone scan index declined gradually, reaching 0.0% 13 months after starting triplet therapy. To evaluate the true efficacy of triplet therapy, regular radiological testing should be performed, similar to regular PSA testing.